CERo reports encouraging early data from phase 1 trial of CER‑1236
CER‑T therapy shows initial safety signals and prompts protocol expansion
Read More
Author: John Pinching
ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
Trial to assess whether once‑weekly treatment can reduce symptomatic viral respiratory infections
Read MoreArgo Biopharma doses first patient in phase 2b trial of BW‑20829
siRNA therapeutic progresses in global study for patients with elevated Lp(a)
Read More
Akari files new patent and advances second ADC targeting CEACAM5
Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate
Read More
BioMed X launches kidney disease project in partnership with the government of Barbados
Initiative focuses on population-specific molecular profiling
Read More- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
